Immunohematology

· 1 paper in corpus
2022
doi:10.21307/immunohematology-2022-036 ·PMID:35852060

According to recent work group recommendations, individuals with the serologic weak D phenotypes should be RHD genotyped and individuals with molecular weak D types 1, 2, 3, 4.0, or 4.1 should be treated as D+. We report an African American…